Abstract | BACKGROUND: METHODS: This study reports a retrospective, interventional case series of nine consecutive patients with ten eyes with newly diagnosed ARN treated with oral valacyclovir as the sole antiviral agent. Eight patients received oral valacyclovir 2 g tid ( Valtrex, GlaxoSmithKline) and one patient with impaired renal function received oral 1 g tid. The main outcome measures were response to treatment, time to initial response to treatment, time to complete resolution of retinitis, best corrected visual acuity (BCVA) at final follow-up, retinal detachment and development of recurrent or second eye disease. RESULTS:
Retinitis resolved in ten of ten (100%) affected eyes. The median time to initial detectable response was seven days and the median time to complete resolution was 21 days. A final BCVA of 20/40 or better was achieved in 6/10 (60%) of eyes. 3/10 eyes (30%) developed a retinal detachment. No patients developed either disease reactivation or second eye involvement over the course of the study (mean follow up 31 weeks, range 7 to 104 weeks). CONCLUSIONS:
|
Authors | Simon Rj Taylor, Robin Hamilton, Claire Y Hooper, Lavnish Joshi, Jiten Morarji, Nitin Gupta, Sue L Lightman |
Journal | BMC ophthalmology
(BMC Ophthalmol)
Vol. 12
Pg. 48
(Sep 05 2012)
ISSN: 1471-2415 [Electronic] England |
PMID | 22947428
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiviral Agents
- Prodrugs
- Valine
- Valacyclovir
- Acyclovir
|
Topics |
- Acyclovir
(administration & dosage, analogs & derivatives)
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Antiviral Agents
(administration & dosage)
- Dose-Response Relationship, Drug
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Prodrugs
- Retinal Necrosis Syndrome, Acute
(diagnosis, drug therapy)
- Retrospective Studies
- Treatment Outcome
- Valacyclovir
- Valine
(administration & dosage, analogs & derivatives)
- Visual Acuity
|